SAR Sareum Holdings Plc

TIDMSAR

RNS Number : 8859W

Sareum Holdings PLC

14 December 2023

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 14 December 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.

Details of the proxy voting results are shown in the table below.

 
 Ordinary             Votes       %      Votes      %       Votes       %        Votes 
  Resolutions          For               Against            Total       of      Withheld 
                                                                        ISC 
                                                                       Voted 
 1. Receive 
  the financial 
  statements 
  for the 
  year              4,955,805   99.3%    33,480    0.7%   4,989,285    7.1%      2,917 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 2. Receive 
  and approve 
  the Directors' 
  Renumeration 
  Report for 
  the year          4,797,240   96.2%   187,995    3.8%   4,985,235    7.1%      6,967 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 3. Re-elect 
  Dr Timothy 
  Mitchell 
  as Director 
  of the Company    4,723,539   94.9%   256,139    5.1%   4,979,678    7.1%     12,524 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 4. Re-elect 
  Dr Stephen 
  Parker as 
  Director 
  of the Company    4,569,986   92.0%   399,292    8.0%   4,969,278    7.1%     22,924 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 5. Re-appoint 
  Shipleys 
  LLP as auditor    4,855,004   98.1%    92,757    1.9%   4,947,761    7.0%     44,441 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 6. Authorise 
  the audit 
  committee 
  to determine 
  auditor 
  renumeration      4,867,151   98.3%    86,553    1.7%   4,953,704    7.1%     38,498 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 7. Directors' 
  authority 
  to allot 
  new shares        4,567,808   92.4%   373,843    7.6%   4,941,651    7.0%     50,551 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 Special 
  Resolution 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 8. Directors' 
  authority 
  to disapply 
  pre-emption 
  rights            4,573,097   92.5%   368,554    7.5%   4,941,651    7.0%     50,551 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 9. Authority 
  to hold 
  general 
  meetings          4,926,142   99.0%    49,243    1.0%   4,975,385    7.1%     16,817 
                   ----------  ------  ---------  -----  ----------  -------  ---------- 
 

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website ( www.sareum.com/investors )

For further information, please contact:

 
 Sareum Holdings plc 
  Tim Mitchell, CEO                                01223 497700 
  Lauren Williams, Head of Investor Relations      ir@sareum.co.uk 
 Strand Hanson Limited (Nominated Adviser) 
  James Dance / James Bellman                      020 7409 3494 
 Peel Hunt LLP (Joint Corporate Broker) 
  James Steel / Patrick Birkholm                   020 7418 8900 
 Hybridan LLP (Joint Corporate Broker) 
  Claire Noyce 
                                                   020 3764 2341 
  ICR Consilium (Financial PR) 
  Jessica Hodgson / Davide Salvi / Stella 
  Lempidaki                                        020 3709 5700 
 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFFDFILEDSEDE

(END) Dow Jones Newswires

December 14, 2023 10:35 ET (15:35 GMT)

Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Sareum (LSE:SAR)
Gráfica de Acción Histórica
De May 2023 a May 2024